01.06.2012
A multicentre, randomised, open-label, Phase IIb trial of afatinib* versus gefitinib, as first line treatment for patients with advanced NSCLC harbouring an EGFR mutation.
Related links:
LUX-Lung 8 Clinical Trial Infographic
Read more >
Lung Cancer Animated Infographic
Read more >LUX-Lung 7 Clinical Trial Infographic
BI @ ASCO 2013
Lung Cancer: Not Just One Disease
New Phase III data for afatinib* and nintedanib...
Lung Cancer: Not Just One Disease
New Phase III data for afatinib* and nintedanib...
BI @ ASCO 2013 <br/>Lung Cancer: Not Just One Disease
BI @ ASCO 2013 <br/>BI to present highly anticipated new Phase III results
BI @ ASCO 2013<br/>New Phase III data for afatinib* and nintedanib*
US FDA Grants Priority Review to Boehringer Ingelheim's Afatinib
Unprecedented progression-free survival benefit with afatinib
Boehringer Ingelheim submits first compound
BI submits first oncology compound, afatinib* f...
BI submits first oncology compound, afatinib* f...
Boehringer Ingelheim submits first compound
Lung Cancer Animated Infographic
EGFR Mutation Backgrounder
Afatinib Backgrounder
LUX-Lung 3 Fact Sheet
Afatinib delivers unprecedented first line efficacy
LUX-Lung 3 Results - Prof James Yang
Interview with Prof James-Chih-Hsin Yang Direc...
Interview with Prof James-Chih-Hsin Yang Direc...
LUX-Lung 3 Results - Prof James Yang
LUX-Lung 7 Clinical Trial Infographic
LUX-Lung 8 Clinical Trial Infographic
Pivotal study on afatinib
Pivotal study on afatinib may challenge standar...
Pivotal study on afatinib may challenge standar...
Pivotal study on afatinib
Cancer statistics and incidence rates
Importance of EGFR Mutation Testing
Interview with Dr Vera Hirsh Associate Profess...
Interview with Dr Vera Hirsh Associate Profess...
Importance of EGFR Mutation Testing
Lung Cancer Backgrounder
LUX-Lung 3 Results - Prof Thomas Lynch
Interview with Prof Thomas J. Lynch, MD Direct...
Interview with Prof Thomas J. Lynch, MD Direct...
LUX-Lung 3 Results - Prof Thomas Lynch
LUX-Lung 3 Trial Design
Interview with Prof Tony Shu Kam Mok, MD Depar...
Interview with Prof Tony Shu Kam Mok, MD Depar...
LUX-Lung 3 Trial Design
LUX-Lung 6 and other Afatinib Trials
Interview with Prof James-Chih-Hsin Yang Direc...
Interview with Prof James-Chih-Hsin Yang Direc...
LUX-Lung 6 and other Afatinib Trials
LUX-Lung 7 & 8 Trials
Interview with Prof Thomas J. Lynch, MD Direct...
Interview with Prof Thomas J. Lynch, MD Direct...
LUX-Lung 7 & 8 Trials
Nintedanib Backgrounder
Targeted Cancer Therapies Backgrounder
Pivotal Phase III Results
Media Alert: Pivotal Phase III Results for Afat...
Media Alert: Pivotal Phase III Results for Afat...
Pivotal Phase III Results
Afatinib
Interview with Prof Thomas J. Lynch, MD Direct...
Interview with Prof Thomas J. Lynch, MD Direct...
Afatinib
Biomarkers
Interview with Prof Thomas J. Lynch, MD Direct...
Interview with Prof Thomas J. Lynch, MD Direct...
Biomarkers
Angiokinase Inhibition and Nintedanib (BIBF 1120) Infographic
BIBF 1120* in mCRC
BIBF 1120* in patients with metastatic colorect...
BIBF 1120* in patients with metastatic colorect...
BIBF 1120* in mCRC
ErbB family Blockade and Afatinib Infographic
LUME Lung 2 clinical trial infographic
LUME-Lung 1 infographic
Lung cancer incidence statics in Europe Infographic
LUX Lung 1 clinical trial fact sheet
LUX Lung 1 Clinical Trial Infographic
LUX Lung 2 clinical cancer trial
LUX Lung 2 Clinical Trial Infographic
LUX-Lung 3 Clinical Trial Layered Infographic
The Changing Face of Cancer Infographic
New Lux-Lung 1 data December 2010
New subgroup analysis of the LUX-Lung 1 trial s...
New subgroup analysis of the LUX-Lung 1 trial s...
New Lux-Lung 1 data December 2010
Angiokinase inhibitors in lung cancer
Interview with Marianne Nicolson, MD, FRCP Con...
Interview with Marianne Nicolson, MD, FRCP Con...
Angiokinase inhibitors in lung cancer
Better lung cancer treatment
Improving outcomes in lung cancer
Personalising cancer care and the future of cancer treatments
Interview with John Heymach, MD, PhD Associate...
Interview with John Heymach, MD, PhD Associate...
Personalising cancer care and the future of cancer treatments
Non small cell lung cancer overview
Interview with David Ross Camidge, MD, PhD As...
Interview with David Ross Camidge, MD, PhD As...
Non small cell lung cancer overview
Afatinib lung cancer trial results
Afatinib (BIBW 2992*) triples progression free ...
Afatinib (BIBW 2992*) triples progression free ...
Afatinib lung cancer trial results
EGFR Mode of Action
Boehringer Ingelheim and DxS sign agreement
Boehringer Ingelheim and DxS sign an agreement ...
Boehringer Ingelheim and DxS sign an agreement ...
Boehringer Ingelheim and DxS sign agreement
Boehringer Ingelheim to commence Lux Lung 3 study
Boehringer Ingelheim and DxS sign agreement for...
Boehringer Ingelheim and DxS sign agreement for...
Boehringer Ingelheim to commence Lux Lung 3 study
Boehringer Ingelheim to present new data at ASCO 2009
Boehringer Ingelheim to Present New Phase II Cl...
Boehringer Ingelheim to Present New Phase II Cl...
Boehringer Ingelheim to present new data at ASCO 2009
Press release LUME-Lung 1+2 November 2008
First pivotal trials begin for Boehringer Ingel...
First pivotal trials begin for Boehringer Ingel...
Press release LUME-Lung 1+2 November 2008
Clinical trials data BIBF 1120*
Data suggests promising overall survival and pr...
Data suggests promising overall survival and pr...
Clinical trials data BIBF 1120*
Lux phase 3 BIBW 2992 (afatinib)
New data on BIBW 2992*, a potent, irreversible,...
New data on BIBW 2992*, a potent, irreversible,...
Lux phase 3 BIBW 2992 (afatinib)
Ovarian cancer backgrounder
AGO-OVAR 12/LUME-Ovar 1 Ovarian Cancer Trial Infographic
State of Research in Ovarian Cancer
Interview with Jonathan Ledermann, BSc, MD, FRC...
Interview with Jonathan Ledermann, BSc, MD, FRC...
State of Research in Ovarian Cancer
Characteristics and Symptoms of Ovarian Cancer
Interview with Ken Swenerton, MD, FRCPC Cancer...
Interview with Ken Swenerton, MD, FRCPC Cancer...
Characteristics and Symptoms of Ovarian Cancer
Ovarian Cancer Prognosis
Interview with Professor Ignace Vergote Chairm...
Interview with Professor Ignace Vergote Chairm...
Ovarian Cancer Prognosis
Targeted Therapies in Ovarian Cancer
Interview with Ken Swenerton, MD, FRCPC Cancer...
Interview with Ken Swenerton, MD, FRCPC Cancer...
Targeted Therapies in Ovarian Cancer
Ovarian Cancer Animated Infographic
Ovarian Cancer Statistics Infographic
LUME-Ovar 1 December 2009
Boehringer Ingelheim initiates first Phase III ...
Boehringer Ingelheim initiates first Phase III ...
LUME-Ovar 1 December 2009
Breast Cancer Backgrounder
LUX-Breast 1 Infographic
LUX-Breast 3 Clinical Trial Infographic
LUX-Breast Clinical Trial Programme Infographic
Breast Cancer Animated Infographic
Lux Breast Cancer Trial August 2011
Boehringer Ingelheim Broadens its Breast Cancer...
Boehringer Ingelheim Broadens its Breast Cancer...
Lux Breast Cancer Trial August 2011
Breast Cancer Statistics Infographic
Could new cancer targets change the outlook for personalised medicine?
Interview with Kathleen Pritchard, MD, FRCPC T...
Interview with Kathleen Pritchard, MD, FRCPC T...
Could new cancer targets change the outlook for personalised medicine?
LUX-Breast 1 Initiation September 2010
Boehringer Ingelheim Initiates Phase III Clinic...
Boehringer Ingelheim Initiates Phase III Clinic...
LUX-Breast 1 Initiation September 2010
Head and Neck Cancer Backgrounder
LUX-Head & Neck 1 & 2 Trial Initiation
BI moves into Phase III for its Head and Neck C...
BI moves into Phase III for its Head and Neck C...
LUX-Head & Neck 1 & 2 Trial Initiation
LUX-Head & Neck 1 Trial Infographic
LUX-Head & Neck 2 Trial Infographic
Head and Neck Cancer
Interview with Ezra Cohen, MD Associate Profes...
Interview with Ezra Cohen, MD Associate Profes...
Head and Neck Cancer
Head and Neck Cancer Treatments
Interview with Ezra Cohen, MD Associate Profes...
Interview with Ezra Cohen, MD Associate Profes...
Head and Neck Cancer Treatments
Head and Neck Cancer Trials
Interview with Ezra Cohen, MD Associate Profes...
Interview with Ezra Cohen, MD Associate Profes...
Head and Neck Cancer Trials
Head and Neck Cancer Infographic
BIBW 2992 cancer treatment data
BI's lead investigational oncology compound BIB...
BI's lead investigational oncology compound BIB...
BIBW 2992 cancer treatment data
Rare disease day Boehringer Ingelheim announces initiation of pivotal trial
Boehringer Ingelheim to initiate Phase III study in leukaemia
Volasertib* and Polo-like kinase (Plk) Inhibition Infographic
Volasertib* (compound code BI 6727)
Volasertib* (compound code BI 6727) is an inves...
Volasertib* (compound code BI 6727) is an inves...
Volasertib* (compound code BI 6727)
Clinical Trials E-Booklet Chapter 1
Introduction & Design of a Clinical Trial
Introduction & Design of a Clinical Trial
Clinical Trials E-Booklet Chapter 1
Clinical Trials E-Booklet Chapter 2
Elements of a Clinical Trial
Elements of a Clinical Trial
Clinical Trials E-Booklet Chapter 2
Clinical Trials E-Booklet Chapter 3
Clinical Trial Endpoints
Clinical Trial Endpoints
Clinical Trials E-Booklet Chapter 3
Clinical Trials E-Booklet Chapter 4
Defining Progression
Defining Progression
Clinical Trials E-Booklet Chapter 4
Clinical Trials E-Booklet Chapter 5
Clinical Trial Statistics
Clinical Trial Statistics
Clinical Trials E-Booklet Chapter 5
Clinical Trials E-Booklet Chapter 6
Summary, Checklist & Glossary
Summary, Checklist & Glossary
Clinical Trials E-Booklet Chapter 6
BI in Oncology Backgrounder
A-Z Cancer Glossary
The terminology around cancer research and canc...
The terminology around cancer research and canc...
A-Z Cancer Glossary
BI accesses field of oncology
BI accesses field of oncology with three compou...
BI accesses field of oncology with three compou...
BI accesses field of oncology
© 2012 Boehringer Ingelheim GmbH. All rights reserved.
More news from Boehringer Ingelheim:
http://www.boehringer-ingelheim.com/news.html
Optimized for IE9 and above.